Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects
Primary Purpose
Nocturia
Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
Desmopressin
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Nocturia
Eligibility Criteria
Inclusion Criteria:
- Written informed consent prior to performance of any trial-related activity
- Man ≥20 years of age
- Nocturia symptoms present for ≥6 months prior to trial entry at Visit 1
- ≥2 nocturnal voids at the end of screening period prior to Visit 2
- Nocturnal polyuria at the end of screening period prior to Visit 2
- Bothered by nocturia on the Hsu 5-point Likert bother scale at Visit 1 and Visit 2
- Has given agreement about contraception during the trial
Exclusion Criteria:
- Evidence of any significant voiding dysfunction resulting in abnormally low bladder capacity at the end of the screening period prior to Visit 2
- History or evidence of significant obstructive sleep apnoea
History or diagnosis of any of the following urological diseases at Visit 1:
- Interstitial cystitis or bladder pain disorder
Suspicion of moderate or severe benign prostate hyperplasia (BPH), defined as international prostate symptom score (IPSS) ≥8 points and:
- Urinary flow <5 mL/s or
- Post-void residual volume >150 mL
- Stress urinary incontinence or mixed incontinence, where stress incontinence is the predominant component based on prior history
- Chronic pelvic pain syndrome
- Surgical treatment, including transurethral resection, for bladder outlet obstruction (BOO) or BPH within the past 6 months prior to Visit 1
Symptoms of severe over-active bladder (OAB):
- Defined as an over-active bladder symptom score (OABSS) ≥12 at Visit 1
- Defined as a mean of >8 voids and a mean of ≥1 urgency episode per 24 hours at the end of the screening period prior to Visit 2
- Genito-urinary tract pathology that can in the investigator's opinion be responsible for urgency or urinary incontinence at Visit 1
- Complication of cancer or a history of cancer which has not been in remission for the last 5 years at Visit 1
- Current or a history of urologic malignancies, any lower urinary tract surgery, previous pelvic irradiation, or neoplasia at Visit 1
- History of any neurological disease affecting bladder function or muscle strength at Visit 1
- Habitual or psychogenic polydipsia based on medical history at Visit 1 or 24 hour urine output of >2.8 L based on the voiding diary at Visit 2
- Central or nephrogenic diabetes insipidus at Visit 1
- Syndrome of inappropriate antidiuretic hormone secretion at Visit 1
- Suspicion or evidence of cardiac failure at Visit 1
- Uncontrolled hypertension at Visit 1
- Uncontrolled diabetes mellitus at Visit 1
- Hyponatraemia (serum sodium level <135 mmol/L) at Visit 1
- Renal insufficiency at Visit 1
- Hepatic and/or biliary diseases at Visit 1
- Known or suspected hypersensitivity to desmopressin ODTs or previous desmopressin treatment for nocturia at Visit 1
- Known alcohol or substance abuse at Visit 1
- Work or lifestyle that may interfere with regular night-time sleep at Visit 1, e.g., shift workers
- Any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity, or language barrier that, in the judgment of the investigator, would impair participation in the trial at Visit 1
- Use of any prohibited therapy during the trial period
Sites / Locations
- Investigational site (there may be other sites in this country)
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
Desmopressin 25 µg
Desmopressin 50 µg
Placebo
Arm Description
Desmopressin ODT
Desmopressin ODT
Placebo ODT
Outcomes
Primary Outcome Measures
Change from baseline in mean number of nocturnal voids during 12 weeks of treatment
Assessed by the 3-day voiding diary
Secondary Outcome Measures
Change from baseline in mean time to first awakening to void
Assessed by the 3-day voiding diary
Change from baseline in mean nocturnal urine volume
Assessed by the 3-day voiding diary
Change from baseline in mean Nocturnal Polyuria Index (NPI)
Assessed by the 3-day voiding diary
Change from baseline in Nocturia-Specific Quality-of-Life Questionnaire (N-QoL)
Change from baseline in Insomnia Severity Index (ISI)
Change from baseline in bother score
Assessed by the Hsu 5-point Likert bother scale
Frequency and severity of adverse events
Full Information
NCT ID
NCT02904759
First Posted
September 14, 2016
Last Updated
September 9, 2019
Sponsor
Ferring Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT02904759
Brief Title
Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects
Official Title
A Randomised, Double-blind, Placebo-controlled, Multi-centre Trial Investigating the Efficacy and Safety of Desmopressin (FE 992026) Orally Disintegrating Tablets During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
September 2016 (Actual)
Primary Completion Date
September 29, 2017 (Actual)
Study Completion Date
September 29, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ferring Pharmaceuticals
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this trial is to demonstrate efficacy of desmopressin ODT against placebo for the treatment of male subjects with nocturia due to nocturnal polyuria, during 12 weeks of treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nocturia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
342 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Desmopressin 25 µg
Arm Type
Experimental
Arm Description
Desmopressin ODT
Arm Title
Desmopressin 50 µg
Arm Type
Experimental
Arm Description
Desmopressin ODT
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo ODT
Intervention Type
Drug
Intervention Name(s)
Desmopressin
Other Intervention Name(s)
FE 992026
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Change from baseline in mean number of nocturnal voids during 12 weeks of treatment
Description
Assessed by the 3-day voiding diary
Time Frame
Week 1, 4, 8 and 12
Secondary Outcome Measure Information:
Title
Change from baseline in mean time to first awakening to void
Description
Assessed by the 3-day voiding diary
Time Frame
Week 1, 4, 8 and 12
Title
Change from baseline in mean nocturnal urine volume
Description
Assessed by the 3-day voiding diary
Time Frame
Week 1, 4, 8 and 12
Title
Change from baseline in mean Nocturnal Polyuria Index (NPI)
Description
Assessed by the 3-day voiding diary
Time Frame
Week 1, 4, 8 and 12
Title
Change from baseline in Nocturia-Specific Quality-of-Life Questionnaire (N-QoL)
Time Frame
Week 8 and 12
Title
Change from baseline in Insomnia Severity Index (ISI)
Time Frame
Week 8 and 12
Title
Change from baseline in bother score
Description
Assessed by the Hsu 5-point Likert bother scale
Time Frame
Week 8 and 12
Title
Frequency and severity of adverse events
Time Frame
From screening to week 12
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Written informed consent prior to performance of any trial-related activity
Man ≥20 years of age
Nocturia symptoms present for ≥6 months prior to trial entry at Visit 1
≥2 nocturnal voids at the end of screening period prior to Visit 2
Nocturnal polyuria at the end of screening period prior to Visit 2
Bothered by nocturia on the Hsu 5-point Likert bother scale at Visit 1 and Visit 2
Has given agreement about contraception during the trial
Exclusion Criteria:
Evidence of any significant voiding dysfunction resulting in abnormally low bladder capacity at the end of the screening period prior to Visit 2
History or evidence of significant obstructive sleep apnoea
History or diagnosis of any of the following urological diseases at Visit 1:
Interstitial cystitis or bladder pain disorder
Suspicion of moderate or severe benign prostate hyperplasia (BPH), defined as international prostate symptom score (IPSS) ≥8 points and:
Urinary flow <5 mL/s or
Post-void residual volume >150 mL
Stress urinary incontinence or mixed incontinence, where stress incontinence is the predominant component based on prior history
Chronic pelvic pain syndrome
Surgical treatment, including transurethral resection, for bladder outlet obstruction (BOO) or BPH within the past 6 months prior to Visit 1
Symptoms of severe over-active bladder (OAB):
Defined as an over-active bladder symptom score (OABSS) ≥12 at Visit 1
Defined as a mean of >8 voids and a mean of ≥1 urgency episode per 24 hours at the end of the screening period prior to Visit 2
Genito-urinary tract pathology that can in the investigator's opinion be responsible for urgency or urinary incontinence at Visit 1
Complication of cancer or a history of cancer which has not been in remission for the last 5 years at Visit 1
Current or a history of urologic malignancies, any lower urinary tract surgery, previous pelvic irradiation, or neoplasia at Visit 1
History of any neurological disease affecting bladder function or muscle strength at Visit 1
Habitual or psychogenic polydipsia based on medical history at Visit 1 or 24 hour urine output of >2.8 L based on the voiding diary at Visit 2
Central or nephrogenic diabetes insipidus at Visit 1
Syndrome of inappropriate antidiuretic hormone secretion at Visit 1
Suspicion or evidence of cardiac failure at Visit 1
Uncontrolled hypertension at Visit 1
Uncontrolled diabetes mellitus at Visit 1
Hyponatraemia (serum sodium level <135 mmol/L) at Visit 1
Renal insufficiency at Visit 1
Hepatic and/or biliary diseases at Visit 1
Known or suspected hypersensitivity to desmopressin ODTs or previous desmopressin treatment for nocturia at Visit 1
Known alcohol or substance abuse at Visit 1
Work or lifestyle that may interfere with regular night-time sleep at Visit 1, e.g., shift workers
Any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity, or language barrier that, in the judgment of the investigator, would impair participation in the trial at Visit 1
Use of any prohibited therapy during the trial period
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Global Clinical Compliance
Organizational Affiliation
Ferring Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Investigational site (there may be other sites in this country)
City
Tokyo
Country
Japan
12. IPD Sharing Statement
Citations:
PubMed Identifier
31397969
Citation
Yamaguchi O, Juul KV, Falahati A, Yoshimura T, Imura F, Kitamura M. Efficacy and safety of 25 and 50 mug desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program. Low Urin Tract Symptoms. 2020 Jan;12(1):8-19. doi: 10.1111/luts.12276. Epub 2019 Aug 9.
Results Reference
result
Learn more about this trial
Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects
We'll reach out to this number within 24 hrs